If confirmed, testing for miR-143 expression could become a routine part of the molecular workup for CRC, alongside KRAS and BRAF mutational analysis, to help oncologists tailor therapeutic strategies based on the tumor’s specific molecular vulnerabilities. Here, KRAS is linked to neoplasm.